Literature DB >> 22842016

Neuroprotective and memory enhancing properties of a dual agonist of the FGF receptor and NCAM.

Maj N Enevoldsen1, Artur Kochoyan, Monika Jurgenson, Külli Jaako, Oksana Dmytriyeva, Peter S Walmod, Jesper D Nielsen, Janne Nielsen, Shizhong Li, Irina Korshunova, Boris Klementiev, Tatiana Novikova, Alexander Zharkovsky, Vladimir Berezin, Elisabeth Bock.   

Abstract

The fibroblast growth factor receptor (FGFR) plays a vital role in the development of the nervous system regulating a multitude of cellular processes. One of the interaction partners of the FGFR is the neural cell adhesion molecule (NCAM), which is known to play an important role in neuronal development, regeneration and synaptic plasticity. Thus, simultaneous activation of FGFR- and NCAM-mediated signaling pathways may be expected to affect processes underlying neurodegenerative diseases. We here report the identification of a peptide compound, Enreptin, capable of interacting with both FGFR and NCAM. We demonstrate that this dual specificity agonist induces phosphorylation of FGFR and differentiation and survival of primary neurons in vitro, and that these effects are inhibited by abrogation of both NCAM and FGFR signaling pathways. Furthermore, Enreptin crosses the blood-brain barrier after subcutaneous administration, enhances long-term memory in normal mice and ameliorates memory deficit in mice with induced brain inflammation. Moreover, Enreptin reduces cognitive impairment and neuronal death induced by Aβ25-35 in a rat model of Alzheimer's disease, and reduces the mortality rate and clinical signs of experimental autoimmune encephalomyelitis in rats. Thus, Enreptin is an attractive candidate for the treatment of neurological diseases.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842016     DOI: 10.1016/j.nbd.2012.07.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  7 in total

1.  Special issue dedicated to Elisabeth Bock.

Authors:  Vladimir Berezin
Journal:  Neurochem Res       Date:  2013-06       Impact factor: 3.996

Review 2.  New insights into the role of fibroblast growth factors in Alzheimer's disease.

Authors:  Ramy Alam; Yara Mrad; Hussein Hammoud; Zahraa Saker; Youssef Fares; Elias Estephan; Hisham F Bahmad; Hayat Harati; Sanaa Nabha
Journal:  Mol Biol Rep       Date:  2021-11-03       Impact factor: 2.316

Review 3.  Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders.

Authors:  Cortney A Turner; Emine Eren-Koçak; Edny G Inui; Stanley J Watson; Huda Akil
Journal:  Semin Cell Dev Biol       Date:  2015-10-23       Impact factor: 7.727

4.  FGF2 and dual agonist of NCAM and FGF receptor 1, Enreptin, rescue neurite outgrowth loss in hippocampal neurons expressing mutated huntingtin proteins.

Authors:  Mirolyuba Ilieva; Troels T Nielsen; Tanja Michel; Stanislava Pankratova
Journal:  J Neural Transm (Vienna)       Date:  2019-09-09       Impact factor: 3.575

5.  Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects.

Authors:  Oksana Dmytriyeva; Stanislava Pankratova; Irina Korshunova; Peter S Walmod
Journal:  Mediators Inflamm       Date:  2016-11-21       Impact factor: 4.711

6.  Artemin and an Artemin-Derived Peptide, Artefin, Induce Neuronal Survival, and Differentiation Through Ret and NCAM.

Authors:  Mirolyuba Ilieva; Janne Nielsen; Irina Korshunova; Kamil Gotfryd; Elisabeth Bock; Stanislava Pankratova; Tanja Maria Michel
Journal:  Front Mol Neurosci       Date:  2019-02-22       Impact factor: 5.639

7.  Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist.

Authors:  Boris Klementiev; Shizhong Li; Irina Korshunova; Oksana Dmytriyeva; Stanislava Pankratova; Peter S Walmod; Laura K Kjær; Mattias S Dahllöf; Morten Lundh; Dan P Christensen; Thomas Mandrup-Poulsen; Elisabeth Bock; Vladimir Berezin
Journal:  J Neuroinflammation       Date:  2014-02-03       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.